The Latest Breaking News from ELDN

Eledon Pharmaceuticals' Lead Asset Fails In Mid-Stage Study, But Pushes Forward With Pivotal Study

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) stock is trading lower on Friday, with a session volume of 15.72 million, compared to its average volume of 1.24 million, according to Benzinga Pro. The company announced results from its Phase 2 BESTOW trial of tegoprubart for the prevention of organ rejection in patients receiving…

Benzinga · Nov 7, 2025

2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780%

These two growth stocks are attractive for investors seeking big upside in exchange for higher risk.

Barchart · Sep 23, 2025

Eledon Pharmaceuticals' Stock Gains As FDA Grants Orphan Drug Designation

Eledon Pharmaceuticals (NASDAQ: ELDN) received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its drug candidate Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation.

Benzinga · Jun 9, 2022